Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03425006 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03425006: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.
NCT03425006 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03425006, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a single center, single arm phase 2 study to establish the safety and efficacy of itacitinib (also known as INCB039110) administered in combination with pembrolizumab in patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC).
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Itacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-06-18 |
| Est. Completion | 2021-10-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03425006
The ClinicalTrials.gov registry entry for NCT03425006 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03425006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03425006 about?
NCT03425006 is a clinical study titled "Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer". This is a single center, single arm phase 2 study to establish the safety and efficacy of itacitinib (also known as INCB039110) administered in combination with pembrolizumab in patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC).
What is the current status of trial NCT03425006?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2018-06-18. Estimated completion is 2021-10-11.
What interventions are being tested in trial NCT03425006?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Itacitinib (DRUG).
Who is sponsoring clinical trial NCT03425006?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.